The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials

D. G. Bostwick^*, H. B. Burke, T. M. Wheeler, L. W.K. Chung, R. Bookstein, T. G. Pretlow, R. B. Nagle, R. Montironi, M. M. Lieber, R. W. Veltri, W. E. Grizzle, D. J. Grignon

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review